GoodRx Holdings, Inc. $GDRX Stock Position Raised by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC increased its stake in GoodRx Holdings, Inc. by 146.6%, acquiring a total of 375,648 shares valued at approximately $1.66 million.
• The company's stock has seen recent analyst downgrades, with UBS reducing its price target from $6.00 to $5.25 and a shift from "strong-buy" to "outperform" by Raymond James Financial.
• GoodRx reported a quarterly earnings miss with an EPS of $0.09 against a consensus estimate of $0.10, alongside revenue of $203.07 million, below expectations of $205.72 million.

Cubist Systematic Strategies LLC boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 146.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 375,648 shares of the company's stock after acquiring an additional 223,336 shares during the period. Cubist Systematic Strategies LLC owned about 0.10% of GoodRx worth $1,657,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Citizens Financial Group Inc. RI purchased a new stake in shares of GoodRx during the 1st quarter valued at $44,000. Jump Financial LLC acquired a new position in GoodRx in the 1st quarter worth $49,000. Northwestern Mutual Wealth Management Co. lifted its holdings in GoodRx by 20,956.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company's stock worth $64,000 after buying an additional 14,460 shares in the last quarter. Headlands Technologies LLC lifted its holdings in GoodRx by 213.2% in the 1st quarter. Headlands Technologies LLC now owns 14,830 shares of the company's stock worth $65,000 after buying an additional 10,095 shares in the last quarter. Finally, Total Wealth Planning & Management Inc. acquired a new position in GoodRx in the 4th quarter worth $68,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $4.05, for a total transaction of $64,864.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GDRX. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.80.

GoodRx Price Performance

Shares of NASDAQ:GDRX traded down $0.02 during trading on Friday, reaching $4.21. The company had a trading volume of 346,514 shares, compared to its average volume of 2,002,565. The firm's fifty day moving average is $4.44 and its 200 day moving average is $4.44. The firm has a market capitalization of $1.46 billion, a PE ratio of 42.05, a price-to-earnings-growth ratio of 1.79 and a beta of 1.23. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $7.82. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. During the same period in the prior year, the company posted $0.08 earnings per share. The company's revenue was up 1.2% on a year-over-year basis. On average, equities analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.